Haemonetics (HAE) Cash Flow Statement

Click line-items for a historical chart and %

Net income	9.48M
Depreciation and amortization	45.25M
Stock compensation expense	4.24M
Loss/(Gain) on sales of property, plant and equipment
Unrealized loss from hedging activities	-1.67M
Accretion of interest expense on contingent consideration
Decrease in accounts receivable, net	6.81M
Increase in inventories	-12.66M
Decrease in prepaid income taxes	-324K
Decrease in other assets and other long-term liabilities	2.84M
Tax benefit on exercise of stock options
Decrease in accounts payable and accrued expenses	6.17M
Net cash provided by operating activities	69.96M
Capital expenditures on property, plant and equipment	-41.62M
Proceeds from sale of property, plant and equipment	197K
Net cash used in investing activities	-41.43M
Payments on long-term real estate mortgage	-18.97M
Net decrease in short-term loans	-1.12M
Employee stock purchase plan	1.98M
Exercise of stock options	13.53M
Excess tax benefit on exercise of stock options
Share repurchase	0
Net cash provided by/(used in) financing activities	-4.58M
Effect of exchange rates on cash and cash equivalents	-211K
Net Increase/(Decrease) in Cash and Cash Equivalents	23.75M
Cash and Cash Equivalents at Beginning of Year	115.12M
Cash and Cash Equivalents at End of Period	138.87M
Transfers from inventory to fixed assets for placements of Haemonetics equipment	3.48M
Interest paid	4.12M
Income taxes paid	3.87M

Entities mentioned with HAE

View All Entities